Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.52 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.52 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.52 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.52 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.37 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.37 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576 | 0.93 | LPAR1 (0.58) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL12983836 | 0.92 | LPAR1 (0.54) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL13552 | 0.91 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL3755 | 0.91 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL4797 | 0.91 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL3222 | 0.90 | LPAR1 (0.50) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL3254 | 0.90 | LPAR1 (0.54) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL3618 | 0.90 | LPAR1 (0.51) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL4664 | 0.89 | LPAR1 (0.49) | LPAR1ABCC3ABCC4ABCB11CYP2C8 | |
| SCHEMBL4264 | 0.89 | ABCC3 (0.49) | LPAR1ABCC3ABCC4ABCB11CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694496-A1 | 3- OR 5 - BI PHENYL - 4 - YLISOXAZOLE - BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN, CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS | Amira Pharmaceuticals, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8541587-B2 | Lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541587-B2 | Lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2012138797-A1 | 3- OR 5 - BI PHENYL - 4 - YLISOXAZOLE - BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN, CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012138797-A1 | 3- OR 5 - BI PHENYL - 4 - YLISOXAZOLE - BASED COMPOUNDS USEFUL FOR THE TREATMENT OF FIBROSIS, PAIN, CANCER AND RESPIRATORY, ALLERGIC, NERVOUS SYSTEM OR CARDIOVASCULAR DISORDERS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120258987-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258987-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258987-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885ABCC3 3302/4885ABCC4 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.